What ChondroFiller costs in the UK

ChondroFiller knee injections in the UK follow a fixed three-tier price structure based on defect size. For a focal cartilage defect of approximately 3 cm², one box of the injectable collagen scaffold costs £3,000. A larger defect of around 4.5 cm² requires two boxes at £5,500, and defects up to the 6 cm² treatment ceiling require three boxes at £8,000. Complex or multi-compartment Grade III/IV presentations can reach £9,800.

These figures are consistent across UK private clinics as of 2026 — they are not individually negotiated, and patients elsewhere in the country should expect the same guide costs they will find at London-based centres.

Each tier is fully bundled. The quoted price covers the pre-injection consultation, imaging review, real-time ultrasound guidance for the in-clinic injection, the ChondroFiller scaffold product itself, IV antibiotic cover, and a six-week follow-up appointment. No additional invoices are generated for those components.

ChondroFiller has no NHS commissioning or GP referral pathway; every patient in the UK funds treatment privately, either through self-payment or private medical insurance with prior written authorisation.

One practical caveat: the tier — and therefore the final cost — cannot be confirmed until a pre-treatment MRI has been reviewed. Defect surface area cannot be reliably estimated from symptoms or examination alone.

What the price includes — and what it doesn't

Anyone who has received a standard UK private orthopaedic quote will be familiar with a long itemised list: a separate consultant fee, an anaesthetist's invoice, theatre time, implant or product costs, and a follow-up charge billed weeks later. ChondroFiller works differently. Because the procedure is an outpatient ultrasound-guided injection rather than a theatre admission, there is no anaesthetist, no theatre time, and no post-operative physio billed on top. The components that private MSK patients routinely receive as separate invoices — imaging review, the injectable scaffold product, antibiotic cover, the injection appointment itself, and a six-week follow-up — are collapsed into the tier price from the outset.

The one genuine additional cost to budget for is the pre-treatment MRI. This scan is mandatory before a tier can be confirmed, because defect surface area cannot be mapped clinically. It is not included in the £3,000–£9,800 guide costs and will typically appear as a separate outpatient imaging charge. Beyond that, the tier price quoted is the substantive total for the treatment episode.

Why defect size drives your cost

The step between each pricing tier — roughly £2,500 from one box to the next — reflects the cost of the scaffold material rather than clinic overhead. ChondroFiller is a murine-derived Type I collagen gel manufactured by Meidrix Biomedicals GmbH in Germany and imported to the UK under prescription as a CE-marked Class III medical device. Each box covers a defined surface area of cartilage; the per-unit uplift is steeper than for most comparable injectable therapies because the material itself is the dominant cost variable, not service fees or room time.

How many boxes are appropriate depends entirely on the surface area of the focal defect. That measurement cannot be made reliably from symptoms or physical examination alone — a defect that produces significant pain may occupy less surface area than one that is clinically quiet, and vice versa. A pre-treatment MRI, ideally with cartilage-specific sequencing, is the only way to map the defect with the precision the tier decision requires. Where available, AI-assisted cartilage segmentation — such as onMRI™ analysis — can sharpen that pre-treatment measurement further by producing quantified surface-area mapping rather than a radiologist's visual estimate.

The MRI is therefore not an administrative hurdle. It is the clinical measurement on which the pricing decision directly rests.

Private medical insurance and pre-authorisation

For patients holding a private medical insurance (PMI) policy, the first question is whether ChondroFiller falls within the covered procedures. It frequently does — Bupa, Aviva, and WPA are the insurers most commonly reported to have granted pre-authorisation — but approval is policy-dependent and should never be assumed in advance.

The practical sequence matters. Contact your insurer before booking any clinical appointment, confirm that the procedure is covered under your specific policy terms, and request written pre-authorisation citing CCSD codes W3111 (cartilage regeneration with collagen scaffold) and W8500. These are the billing codes under which ChondroFiller is submitted; having them to hand speeds up the authorisation conversation considerably. Written pre-authorisation must be in place before treatment begins — not applied for retrospectively.

Even with approval, partial coverage is common. Most PMI policies carry an annual excess, and some cap individual treatment episodes. Against guide costs of £3,000–£9,800, it is worth establishing precisely what your policy will and will not fund before committing to a date, so that any patient contribution is clear in advance rather than discovered on the invoice.

For patients without applicable cover, treatment is funded privately. ChondroFiller sits outside NHS commissioning, so self-funding and PMI are the two available routes. The fixed-tier structure — with consultation, imaging review, the scaffold product, antibiotic cover, and follow-up all included — means that whatever the patient contribution turns out to be after any insurance offset, it carries no hidden additions on top.

How ChondroFiller pricing sits within the UK cartilage treatment market

The UK private cartilage repair market runs from approximately £4,000 for microfracture to around £28,000 for single-stage implantation procedures. ChondroFiller's injection pathway — starting at £3,000 for a single focal defect — sits at the accessible lower-to-mid range of that spectrum, though the comparison requires care: microfracture may be lower in upfront cost but yields fibrocartilage rather than the hyaline-like tissue that scaffold-based approaches aim to support.

For patients whose defect or symptoms call for more than the scaffold alone, combination pathways extend the cost upward. Pairing ChondroFiller with Arthrosamid — a polyacrylamide hydrogel that integrates into the synovial lining to modify the joint environment — brings the combined guide cost to approximately £6,000. The Tri-Active MSC pathway, which adds autologous mesenchymal stem cells, rises to around £11,000. When costing a combination, it is important to understand that ChondroFiller and Arthrosamid are addressing different problems: ChondroFiller is the regenerative scaffold component, recruiting the patient's own progenitor cells through acellular matrix-induced chondrogenesis; Arthrosamid acts on the joint environment rather than the cartilage surface. Their costs reflect separate mechanisms and should not be read as redundant overlap.

No formal health-economic analysis specific to ChondroFiller in the knee is currently available; the published evidence base covers clinical outcomes rather than cost-effectiveness modelling. What that outcome data does indicate — an IKDC improvement of approximately 30 points at 12 months — combined with an outpatient recovery of one to two weeks rather than the months required after surgical alternatives, suggests that for a patient with a single focal defect, the injection pathway carries substantially less total burden than its surgical counterparts at a comparable or lower entry cost.

Recovery burden and what patients should plan for

One to two weeks of reduced activity is the typical post-treatment window following ChondroFiller injection — a meaningful contrast to the six to twenty-four months of rehabilitation that surgical cartilage repair procedures commonly require.

The appointment itself is outpatient. There is no theatre admission and no general anaesthetic for the injection; most patients leave the clinic the same day. For those in sedentary or desk-based roles, the practical disruption is modest. Patients in physically demanding jobs — manual trades, nursing, active caring roles — should include realistic work-absence cost alongside the procedure fee in their total calculation, since that absence can be material to the overall burden.

For patients comparing injection against surgical alternatives on value grounds, shorter recovery is a genuine and fair differentiator — not simply a convenience. The reduced disruption to employment, family commitments, and daily function is part of what the procedure costs, not a separate consideration.

Booking an assessment

Lincolnshire Knee is part of the MSK Doctors group and accepts patients without a GP referral. An assessment — including the MRI imaging review required to confirm defect size and applicable tier — can be booked directly at lincolnshireknee.co.uk.